What Medicinrådet does

Medicinrådet (the Danish Medicines Council) is an independent governmental health technology assessment (HTA) body established on January 1, 2017 by the board of Danish Regions (Danske Regioner). Headquartered in Copenhagen at Dampfærgevej 21-23 with 92 employees, the organization evaluates new medicines for use in the Danish hospital sector through structured 14, 16, or 18-week assessment processes, issuing formal recommendations categorized as "anbefalet" (recommended), "delvist anbefalet" (partially recommended), or "ikke anbefalet" (not recommended). Its outputs are the primary evidence base used by Amgros, the regional pharmaceutical procurement organization, to negotiate medicine prices on behalf of Denmark's five regions, making Medicinrådet's assessments operationally binding for hospital procurement across the country.

The Council's product portfolio centers on a searchable recommendations database (Anbefalingsdatabase) containing 376+ medicine assessments to date, treatment guidelines (Behandlingsvejledninger) that prioritize medicines within specific disease areas, and primary-sector tools including the Basislisten (basic medicines list) and Seponeringslisten (discontinuation list). It also publishes general recommendations for drug classes (e.g., PD-(L)1 inhibitors for metastatic cancer) and participates in joint European HTA assessments. In 2026, the Council launched two pilot projects with the Danish Alliance for Real-World Evidence (DARE) to analyze post-market effectiveness of recommended cancer medicines, signaling expansion into real-world data analytics.

Medicinrådet operates as a non-commercial public entity funded entirely through the Danish healthcare system administrative budget by Danske Regioner, with no product sales, fees, or licensing revenue. It does not develop technology products; rather, its "technology" is its evidence evaluation methodology, prioritization principles (independence, effectiveness documentation, cost-effectiveness, etc.), and integration with the regional procurement system. Pharmaceutical companies engage the Council by submitting assessment applications, and recommendations directly shape which medicines are procured and reimbursed across Danish hospitals. The organization also maintains an active LinkedIn presence and email newsletter, using medicinraadet.dk as its primary dissemination channel for recommendations, guidelines, and news.

Name

Medicinrådet

Legal name

Medicinrådet

Website

https://medicinraadet.dk

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

Medicinrådet (Danish Medicines Council) is an independent governmental health technology assessment body, established in 2017 by Danish Regions, that evaluates and recommends new hospital medicines for Denmark's five regional healthcare authorities, guiding national procurement and price negotiations.

Ownership category

akta.pro rank

Product category

Health Technology Assessment

NAICS

Administration of Public Health Programs (923120), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Health Technology Assessment (HTA) & Reimbursement Policy Bodies (HLAJACAF)

akta.pro secondary industries

Economic Evaluation & Health Technology Assessment (Public Programs) (HLAJANAL), Value Dossier & Evidence Generation (AMCP/Global Value Dossier) (HLAIAKAC), Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN)

Keywords

• Health technology assessment
• Medicine recommendations
• Clinical guidelines
• Hospital drug evaluation
• Pharmaceutical assessment

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Revenue model

1. Governmental funding: Medicinrådet is a governmental body established by Danish Regions (Regionernes Lønnings- og Takstnævn) on January 1, 2017. It does not generate commercial revenue. The organization is funded through the Danish healthcare system administrative budget, not through product sales or fees.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Medicinrådet is a governmental Health Technology Assessment (HTA) body that evaluates new medicines for the Danish hospital sector, producing evidence-based recommendations used to guide procurement across Danish hospitals and regions. The organization assesses applications from pharmaceutical companies through structured processes, issuing recommendations classified as recommended, partially recommended, or not recommended, which then serve as the basis for price negotiations conducted by Amgros.

Product overview

Medicinrådet (Danish Medicines Council) operates as a unified guidance platform providing independent recommendations on new medicines for the Danish hospital sector. The core offering consists of a recommendations database with 376 total assessments across three recommendation categories (232 recommended, 35 partially recommended, 109 not recommended), complemented by treatment guidelines (Behandlingsvejledninger) that prioritize medicines for specific diseases. For primary healthcare, the organization maintains the Basislisten (basic medicines list) and Seponeringslisten (discontinuation list). Additional products include general immunotherapy recommendations for metastatic cancer, participation in joint European HTA assessments, and real-world data partnerships for post-market surveillance.

Differentiator

Problem solved

Functional benefit

Products and services

• Recommendations Database (Anbefalingsdatabase) A searchable database of all medicine assessments, recommendations, and treatment guidelines issued by Medicinrådet, containing 232 recommended, 35 partially recommended, and 109 not recommended medicines. It is used by Danish Regions, hospitals, pharmaceutical companies, and healthcare professionals to access authoritative recommendations.
• Treatment Guidelines (Behandlingsvejledninger) Treatment guidelines that compare multiple medicines for specified diseases and produce a prioritized list of recommended medicines for patients. Used by Danish hospital clinicians and procurement teams to standardize treatment selection.
• Medicine Recommendations (Lægemiddelrekommandationer) Prioritized recommendations for medicines within specific disease areas, serving as a guide for hospital treatment decisions across Danish Regions.
• General Recommendation for Immunotherapy for Metastatic Cancer General recommendation covering PD-(L)1 inhibitors and similar immunotherapy drug classes for metastatic cancer, applicable across multiple indications within Medicinrådet's scope.
• Basislisten (Basic List) National basic list for general practitioners providing recommended medicines for primary healthcare settings. Used by primary care physicians across Denmark to guide first-line prescribing.
• Seponeringslisten (Discontinuation List) List of medicines that should be discontinued or replaced in primary sector treatment guidelines. Used by general practitioners to update prescribing practices.
• Preparation Notifications (Præparatanmeldelser) Notifications of new medicines for primary sector healthcare providers, enabling quick awareness of new drug approvals. Used by general practitioners to stay informed about newly available primary-sector medicines.
• Joint European Assessments (Fælles europæiske vurderinger) Participation in joint European health technology assessments (HTA) with other Nordic and European bodies, producing collaborative assessments for cross-border use.
• Real-World Data Partnership (Partnerskab for real-world data) Collaboration with the Danish Alliance for Real-World Evidence (DARE) to analyze real-world effectiveness data of recommended medicines, supporting post-market surveillance and assessment refinement.

Quantifiable outcome

• 376+ medicine assessments completed with 232 recommended, 35 partially recommended, and 109 not recommended
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and flagship.

• Danish Alliance for Real-World Evidence (DARE)coreStrategic or Co-development Partner · 1 January 2026In 2026, Medicinrådet initiated two pilot projects with DARE (Danish Alliance for Real-World Evidence) to examine the effectiveness of Medicinrådets cancer drug recommendations. DARE will analyze data on the effects of recommended medicines.
• Danish RegionsflagshipOthersMedicinrådet was established on January 1, 2017 by the board of Danish Regions (Regionernes Lønnings- og Takstnævn). Danish Regions is the parent organization that established Medicinrådet based on experiences from previous initiatives such as RADS and KRIS.
• AmgroscoreStrategic or Co-development PartnerAmgros is the pharmaceutical procurement organization that handles price negotiations with pharmaceutical companies on behalf of Danish Regions. Medicinrådets assessments provide the evidence base and recommendations that Amgros uses in its price negotiations, improving the negotiation foundation.
• DARE (Danish Alliance for Real-World Evidence)coreStrategic or Co-development PartnerCollaboration on real-world data (RWD) to analyze the effectiveness of recommended medicines in clinical practice.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• NICE (National Institute for Health and Care Excellence): UK's national HTA body issuing clinical and cost-effectiveness recommendations for NHS-funded medicines. Directly comparable to Medicinrådet as the most influential national HTA agency, sharing the same single-payer HTA logic, recommendation taxonomy, and NHS-style pricing/negotiation integration.
• Zorginstituut Nederland (ZIN): Netherlands' HTA body managing the GVS/conditional reimbursement system for hospital drugs. Comparable in establishing reimbursement conditions tied to outcomes and in collaborating with the Ministry of Health on managed entry agreements.
• TLV (Tandvårds- och läkemedelsförmånsverket): Sweden's Dental and Pharmaceutical Benefits Agency that decides which medicines are subsidized. Directly comparable as a Nordic counterpart with similar scope, population size, and side-by-side HTA + pricing function — likely the most culturally analogous peer.
• IQWiG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen): Germany's independent HTA body producing benefit assessments (early benefit assessment, Nutzenbewertung) that inform GKV-Spitzenverband price negotiations. Directly comparable in mandate and independence principle, though operates in a larger market and within AMNOG framework.
• AIFA (Agenzia Italiana del Farmaco): Italy's national medicines agency combining regulatory, HTA, and pricing/pricing negotiation functions. Comparable as a state agency integrating scientific assessment with reimbursement decisions.
• HAS (Haute Autorité de Santé): France's national HTA authority issuing SMR/ASMR opinions that drive price negotiations with CEPS. Directly comparable as a multi-pillar HTA body covering clinical benefit, economic assessment, and public health guidance within a single-payer system.
• NoMA (Statens legemiddelverk): Norwegian Medicines Agency handling HTA/market access decisions for Norway. Nordic peer with the closest regional context to Denmark and parallel collaboration in joint Nordic HTA initiatives.
• INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde): Portugal's national medicines authority handling HTA and pricing within the NHS. Comparable smaller-market EU HTA body with similar scope and statutory independence.

Market position

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medicinraadet

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicinrådet